The aforementioned evidence strongly suggests that tumor-produced, PGE2-activated immune-suppressive cell species in the TME inhibit the tumoricidal function of effector CD8+ T cells in the tumor through EP4 signaling, and that the EP4 antagonist rescues the tumoricidal function of CD8+ T cells (Figure 1). This evidence concerns the gene PTGER4 and neoplasm.